Progressive de novo DNA methylation at the bcr-abl locus in the course of chronic myelogenous leukemia.
Open accessThe DOI matches its Crossref record.
Abstract
De novo methylation of CpG islands is a rare event in mammalian cells. It has been observed in the course of developmental processes, such as X chromosome inactivation and genomic imprinting. The methylation of DNA, an important factor in the epigenetic control of gene expression, may also be involved in tumorigenesis. After the t(9;22) chromosomal translocation and generation of the Philadelphia chromosome, the initiating event in chronic myelogenous leukemia (CML), most of the abl coding sequence is fused to the 5' region of the bcr gene. Expression of the hybrid bcr-abl gene is, therefore, regulated by the bcr promoter. In most cases of CML, one of the two abl promoters (Pa) is nested within the bcr-abl transcriptional unit and should be able to transcribe the type Ia 6-kb normal abl mRNA from the Philadelphia chromosome. However, we have found that the 6-kb transcript is present only in CML cell lines containing a normal abl allele and that the apparent inactivation of the nested Pa promoter is associated with allele-specific methylation. Furthermore, we have noticed that the Pa promoter is contained within a CpG island and undergoes progressive de novo methylation in the course of the disease. This is attested to by the fact that DNA samples from CML patients that are methylation-free at the time of diagnosis invariably become methylated in advanced CML. Since tumor progression in CML cannot always be inferred from the clinical presentation, assessment of de novo CpG methylation may prove to be of critical value in management of the disease. It could herald blastic transformation at a stage when bone marrow transplantation, the only potentially curative therapeutic procedure in CML, is still effective.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Jones, P. A. (1999) · Trends in Genetics · doi:10.1016/s0168-9525(98)01636-9 · Cited by 665
Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas.
Yoshiura, K., Kanai, Y., Ochiai, A., Shimoyama, Y., Sugimura, T., & Hirohashi, S. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.16.7416 · Cited by 645
THE ROLE OF DNA METHYLATION IN CANCER GENETICS AND EPIGENETICS
Laird, P. W., & Jaenisch, R. (1996) · Annual Review of Genetics · doi:10.1146/annurev.genet.30.1.441 · Cited by 472
Cytogenetic and Molecular Genetic Evolution of Chronic Myeloid Leukemia
Johansson, B., Fioretos, T., & Mitelman, F. (2002) · Acta Haematologica · doi:10.1159/000046636 · Cited by 454
Cross, S. H., & Bird, A. P. (1995) · Current Opinion in Genetics & Development · doi:10.1016/0959-437x(95)80044-1 · Cited by 450
Metadata
- Authors
- Zion, M., Ben-Yehuda, D., Avraham, A., Cohen, O., Wetzler, M., Melloul, D., & Ben-Neriah, Y.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1994-10-25
- Volume
- 91
- Issue
- 22
- Pages
- 10722-10726
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1985014165
- Cited by
- 103
- References
- 0
- FWCI
- 1.59
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Progressive de novo DNA methylation at the bcr-abl locus in the course of chronic myelogenous leukemia. https://app.cochat.ai/papers/10.1073/pnas.91.22.10722
- The paper
- Zion, M., Ben-Yehuda, D., Avraham, A., Cohen, O., Wetzler, M., Melloul, D., & Ben-Neriah, Y. (1994). Progressive de novo DNA methylation at the bcr-abl locus in the course of chronic myelogenous leukemia. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.91.22.10722
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.